Search results
Results From The WOW.Com Content Network
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
GENEVA/ZURICH (Reuters) - The world's master list of recommended medicines got an update on Tuesday when the World Health Organization (WHO) published a biennial revision, adding 28 drugs ...
An increase in cancer cases in the area was confirmed by the Turkish Medical Association, [34] as the cancer rate in the affected area has increased by 80%, from 1999 to April 2002. [33] In 2003, the owner of Aksa Akrilik died from lung cancer related to acrylonitrile exposure. [ 33 ]
Description of the list of classifications Archived 2013-07-28 at the Wayback Machine, IARC. List of Classifications (latest version) List of classifications by cancer site Archived 2012-09-20 at the Wayback Machine (last updated on 5 November 2015)
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. [1] They fall under the category of tyrosine kinase inhibitors , which work by inhibiting proteins involved in the abnormal growth of tumour cells.
J&J discontinues dengue drug study after changes in R&D portfolio. October 4, 2024 at 2:11 PM (Reuters) - Johnson & Johnson said on Friday it will discontinue a mid-stage field study of its ...